Scleroderma Therapeutics Market Forecast to 2027 - COVID-19 Impact and Global Analysis By Drug Class (Immunosuppressors, Prostacyclin Analogues, Calcium Channel Blockers, Phosphodiesterase 5 Inhibitors - PHA, Endothelin Receptor Antagonists, Analgesics, Others); Indication (Systemic, Localized)

Report Code: TIPRE00020949 | No. of Pages: 150 | Category: Pharmaceuticals | Status: Upcoming
Covid
MARKET INTRODUCTION

Scleroderma is a long-term disease that affects skin, connective tissue, and internal organs. The condition is caused when the immune system causes the body to produce high levels of protein collagen which is a vital part of skin. This results in tightening of skin, joint pain and scars can form on lungs and kidneys.

MARKET DYNAMICS

The scleroderma therapeutics market is driving due to off-label use of drugs approved for its symptoms, such as rheumatoid arthritis and development of biologics for scleroderma. Moreover, growing pharmaceutical industry in developing region may create growth opportunities for the market.

MARKET SCOPE

The "Scleroderma Therapeutics Market Analysis to 2027" is a specialized and in-depth study of the healthcare industry with a special focus on the global market trend analysis. The report aims to provide an overview of scleroderma therapeutics market with detailed market segmentation by drug class and indication. The scleroderma therapeutics market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading players in scleroderma therapeutics market and offers key trends and opportunities in the market.

MARKET SEGMENTATION

The scleroderma therapeutics market is segmented on the basis of drug class and indication. Based on drug class, the market is segmented as immunosuppressors, prostacyclin analogues, calcium channel blockers, phosphodiesterase 5 inhibitors - PHA, endothelin receptor antagonists, analgesics, others. The indication segment is segmented into systemic, and localized.

REGIONAL FRAMEWORK

The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the scleroderma therapeutics market based on various segments. It also provides market size and forecast estimates from year 2017 to 2027 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The scleroderma therapeutics market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.

The report analyzes factors affecting scleroderma therapeutics market from both demand and supply side and further evaluates market dynamics affecting the market during forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the Scleroderma therapeutics market in these regions.



Get more information on this report :

MARKET PLAYERS


The report covers key developments in the scleroderma therapeutics market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market players from scleroderma therapeutics market are anticipated to have lucrative growth opportunities in the future with the rising demand for scleroderma therapeutics in the global market. Below mentioned is the list of few companies engaged in the scleroderma therapeutics market.

The report also includes the profiles of key players in scleroderma therapeutics market along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.

  •   F. Hoffman La Roche
  •   Boehringer Ingelheim International GmbH
  •   Bristol-Myers Squibb Company
  •   arGentis Pharmaceuticals LLC
  •   Prometic Life Sciences Inc.
  •   Akashi Therapeutics
  •   Kadmon Holdings Inc.
  •   Emerald Health Pharmaceuticals
  •   Cytori Therapeutics Inc
  •   Bayer

The Insight Partner's dedicated research and analysis team consists of experienced professionals with advanced statistical expertise and offers various customization options in the existing study.


Get more information on this report :

TABLE OF CONTENTS

1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Scleroderma Therapeutics Market - By Drug Class
1.3.2 Scleroderma Therapeutics Market - By Indication
1.3.3 Scleroderma Therapeutics Market - By Region
1.3.3.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. SCLERODERMA THERAPEUTICS MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. SCLERODERMA THERAPEUTICS MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. SCLERODERMA THERAPEUTICS MARKET - GLOBAL MARKET ANALYSIS
6.1. SCLERODERMA THERAPEUTICS - GLOBAL MARKET OVERVIEW
6.2. SCLERODERMA THERAPEUTICS - GLOBAL MARKET AND FORECAST TO 2028
6.3. MARKET POSITIONING/MARKET SHARE
7. SCLERODERMA THERAPEUTICS MARKET - REVENUE AND FORECASTS TO 2028 - DRUG CLASS
7.1. OVERVIEW
7.2. DRUG CLASS MARKET FORECASTS AND ANALYSIS
7.3. IMMUNOSUPPRESSORS
7.3.1. Overview
7.3.2. Immunosuppressors Market Forecast and Analysis
7.4. PROSTACYCLIN ANALOGUES
7.4.1. Overview
7.4.2. Prostacyclin Analogues Market Forecast and Analysis
7.5. CALCIUM CHANNEL BLOCKERS
7.5.1. Overview
7.5.2. Calcium Channel Blockers Market Forecast and Analysis
7.6. PHOSPHODIESTERASE 5 INHIBITORS - PHA
7.6.1. Overview
7.6.2. Phosphodiesterase 5 Inhibitors - PHA Market Forecast and Analysis
7.7. ENDOTHELIN RECEPTOR ANTAGONISTS
7.7.1. Overview
7.7.2. Endothelin Receptor Antagonists Market Forecast and Analysis
7.8. ANALGESICS
7.8.1. Overview
7.8.2. Analgesics Market Forecast and Analysis
7.9. OTHERS
7.9.1. Overview
7.9.2. Others Market Forecast and Analysis
8. SCLERODERMA THERAPEUTICS MARKET - REVENUE AND FORECASTS TO 2028 - INDICATION
8.1. OVERVIEW
8.2. INDICATION MARKET FORECASTS AND ANALYSIS
8.3. SYSTEMIC
8.3.1. Overview
8.3.2. Systemic Market Forecast and Analysis
8.4. LOCALIZED
8.4.1. Overview
8.4.2. Localized Market Forecast and Analysis
9. SCLERODERMA THERAPEUTICS MARKET REVENUE AND FORECASTS TO 2028 - GEOGRAPHICAL ANALYSIS
9.1. NORTH AMERICA
9.1.1 North America Scleroderma Therapeutics Market Overview
9.1.2 North America Scleroderma Therapeutics Market Forecasts and Analysis
9.1.3 North America Scleroderma Therapeutics Market Forecasts and Analysis - By Drug Class
9.1.4 North America Scleroderma Therapeutics Market Forecasts and Analysis - By Indication
9.1.5 North America Scleroderma Therapeutics Market Forecasts and Analysis - By Countries
9.1.5.1 United States Scleroderma Therapeutics Market
9.1.5.1.1 United States Scleroderma Therapeutics Market by Drug Class
9.1.5.1.2 United States Scleroderma Therapeutics Market by Indication
9.1.5.2 Canada Scleroderma Therapeutics Market
9.1.5.2.1 Canada Scleroderma Therapeutics Market by Drug Class
9.1.5.2.2 Canada Scleroderma Therapeutics Market by Indication
9.1.5.3 Mexico Scleroderma Therapeutics Market
9.1.5.3.1 Mexico Scleroderma Therapeutics Market by Drug Class
9.1.5.3.2 Mexico Scleroderma Therapeutics Market by Indication
9.2. EUROPE
9.2.1 Europe Scleroderma Therapeutics Market Overview
9.2.2 Europe Scleroderma Therapeutics Market Forecasts and Analysis
9.2.3 Europe Scleroderma Therapeutics Market Forecasts and Analysis - By Drug Class
9.2.4 Europe Scleroderma Therapeutics Market Forecasts and Analysis - By Indication
9.2.5 Europe Scleroderma Therapeutics Market Forecasts and Analysis - By Countries
9.2.5.1 Germany Scleroderma Therapeutics Market
9.2.5.1.1 Germany Scleroderma Therapeutics Market by Drug Class
9.2.5.1.2 Germany Scleroderma Therapeutics Market by Indication
9.2.5.2 France Scleroderma Therapeutics Market
9.2.5.2.1 France Scleroderma Therapeutics Market by Drug Class
9.2.5.2.2 France Scleroderma Therapeutics Market by Indication
9.2.5.3 Italy Scleroderma Therapeutics Market
9.2.5.3.1 Italy Scleroderma Therapeutics Market by Drug Class
9.2.5.3.2 Italy Scleroderma Therapeutics Market by Indication
9.2.5.4 Spain Scleroderma Therapeutics Market
9.2.5.4.1 Spain Scleroderma Therapeutics Market by Drug Class
9.2.5.4.2 Spain Scleroderma Therapeutics Market by Indication
9.2.5.5 United Kingdom Scleroderma Therapeutics Market
9.2.5.5.1 United Kingdom Scleroderma Therapeutics Market by Drug Class
9.2.5.5.2 United Kingdom Scleroderma Therapeutics Market by Indication
9.2.5.6 Rest of Europe Scleroderma Therapeutics Market
9.2.5.6.1 Rest of Europe Scleroderma Therapeutics Market by Drug Class
9.2.5.6.2 Rest of Europe Scleroderma Therapeutics Market by Indication
9.3. ASIA-PACIFIC
9.3.1 Asia-Pacific Scleroderma Therapeutics Market Overview
9.3.2 Asia-Pacific Scleroderma Therapeutics Market Forecasts and Analysis
9.3.3 Asia-Pacific Scleroderma Therapeutics Market Forecasts and Analysis - By Drug Class
9.3.4 Asia-Pacific Scleroderma Therapeutics Market Forecasts and Analysis - By Indication
9.3.5 Asia-Pacific Scleroderma Therapeutics Market Forecasts and Analysis - By Countries
9.3.5.1 Australia Scleroderma Therapeutics Market
9.3.5.1.1 Australia Scleroderma Therapeutics Market by Drug Class
9.3.5.1.2 Australia Scleroderma Therapeutics Market by Indication
9.3.5.2 China Scleroderma Therapeutics Market
9.3.5.2.1 China Scleroderma Therapeutics Market by Drug Class
9.3.5.2.2 China Scleroderma Therapeutics Market by Indication
9.3.5.3 India Scleroderma Therapeutics Market
9.3.5.3.1 India Scleroderma Therapeutics Market by Drug Class
9.3.5.3.2 India Scleroderma Therapeutics Market by Indication
9.3.5.4 Japan Scleroderma Therapeutics Market
9.3.5.4.1 Japan Scleroderma Therapeutics Market by Drug Class
9.3.5.4.2 Japan Scleroderma Therapeutics Market by Indication
9.3.5.5 South Korea Scleroderma Therapeutics Market
9.3.5.5.1 South Korea Scleroderma Therapeutics Market by Drug Class
9.3.5.5.2 South Korea Scleroderma Therapeutics Market by Indication
9.3.5.6 Rest of Asia-Pacific Scleroderma Therapeutics Market
9.3.5.6.1 Rest of Asia-Pacific Scleroderma Therapeutics Market by Drug Class
9.3.5.6.2 Rest of Asia-Pacific Scleroderma Therapeutics Market by Indication
9.4. MIDDLE EAST AND AFRICA
9.4.1 Middle East and Africa Scleroderma Therapeutics Market Overview
9.4.2 Middle East and Africa Scleroderma Therapeutics Market Forecasts and Analysis
9.4.3 Middle East and Africa Scleroderma Therapeutics Market Forecasts and Analysis - By Drug Class
9.4.4 Middle East and Africa Scleroderma Therapeutics Market Forecasts and Analysis - By Indication
9.4.5 Middle East and Africa Scleroderma Therapeutics Market Forecasts and Analysis - By Countries
9.4.5.1 South Africa Scleroderma Therapeutics Market
9.4.5.1.1 South Africa Scleroderma Therapeutics Market by Drug Class
9.4.5.1.2 South Africa Scleroderma Therapeutics Market by Indication
9.4.5.2 Saudi Arabia Scleroderma Therapeutics Market
9.4.5.2.1 Saudi Arabia Scleroderma Therapeutics Market by Drug Class
9.4.5.2.2 Saudi Arabia Scleroderma Therapeutics Market by Indication
9.4.5.3 U.A.E Scleroderma Therapeutics Market
9.4.5.3.1 U.A.E Scleroderma Therapeutics Market by Drug Class
9.4.5.3.2 U.A.E Scleroderma Therapeutics Market by Indication
9.4.5.4 Rest of Middle East and Africa Scleroderma Therapeutics Market
9.4.5.4.1 Rest of Middle East and Africa Scleroderma Therapeutics Market by Drug Class
9.4.5.4.2 Rest of Middle East and Africa Scleroderma Therapeutics Market by Indication
9.5. SOUTH AND CENTRAL AMERICA
9.5.1 South and Central America Scleroderma Therapeutics Market Overview
9.5.2 South and Central America Scleroderma Therapeutics Market Forecasts and Analysis
9.5.3 South and Central America Scleroderma Therapeutics Market Forecasts and Analysis - By Drug Class
9.5.4 South and Central America Scleroderma Therapeutics Market Forecasts and Analysis - By Indication
9.5.5 South and Central America Scleroderma Therapeutics Market Forecasts and Analysis - By Countries
9.5.5.1 Brazil Scleroderma Therapeutics Market
9.5.5.1.1 Brazil Scleroderma Therapeutics Market by Drug Class
9.5.5.1.2 Brazil Scleroderma Therapeutics Market by Indication
9.5.5.2 Argentina Scleroderma Therapeutics Market
9.5.5.2.1 Argentina Scleroderma Therapeutics Market by Drug Class
9.5.5.2.2 Argentina Scleroderma Therapeutics Market by Indication
9.5.5.3 Rest of South and Central America Scleroderma Therapeutics Market
9.5.5.3.1 Rest of South and Central America Scleroderma Therapeutics Market by Drug Class
9.5.5.3.2 Rest of South and Central America Scleroderma Therapeutics Market by Indication
10. IMPACT OF COVID-19 PANDEMIC ON GLOBAL SCLERODERMA THERAPEUTICS MARKET
10.1 North America
10.2 Europe
10.3 Asia-Pacific
10.4 Middle East and Africa
10.5 South and Central America
11. INDUSTRY LANDSCAPE
11.1. MERGERS AND ACQUISITIONS
11.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
11.3. NEW PRODUCT LAUNCHES
11.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
12. SCLERODERMA THERAPEUTICS MARKET, KEY COMPANY PROFILES
12.1. F. HOFFMAN LA ROCHE
12.1.1. Key Facts
12.1.2. Business Description
12.1.3. Products and Services
12.1.4. Financial Overview
12.1.5. SWOT Analysis
12.1.6. Key Developments
12.2. BOEHRINGER INGELHEIM INTERNATIONAL GMBH
12.2.1. Key Facts
12.2.2. Business Description
12.2.3. Products and Services
12.2.4. Financial Overview
12.2.5. SWOT Analysis
12.2.6. Key Developments
12.3. BRISTOL-MYERS SQUIBB COMPANY
12.3.1. Key Facts
12.3.2. Business Description
12.3.3. Products and Services
12.3.4. Financial Overview
12.3.5. SWOT Analysis
12.3.6. Key Developments
12.4. ARGENTIS PHARMACEUTICALS, LLC
12.4.1. Key Facts
12.4.2. Business Description
12.4.3. Products and Services
12.4.4. Financial Overview
12.4.5. SWOT Analysis
12.4.6. Key Developments
12.5. PROMETIC LIFE SCIENCES INC.
12.5.1. Key Facts
12.5.2. Business Description
12.5.3. Products and Services
12.5.4. Financial Overview
12.5.5. SWOT Analysis
12.5.6. Key Developments
12.6. AKASHI THERAPEUTICS
12.6.1. Key Facts
12.6.2. Business Description
12.6.3. Products and Services
12.6.4. Financial Overview
12.6.5. SWOT Analysis
12.6.6. Key Developments
12.7. KADMON HOLDINGS, INC.
12.7.1. Key Facts
12.7.2. Business Description
12.7.3. Products and Services
12.7.4. Financial Overview
12.7.5. SWOT Analysis
12.7.6. Key Developments
12.8. EMERALD HEALTH PHARMACEUTICALS
12.8.1. Key Facts
12.8.2. Business Description
12.8.3. Products and Services
12.8.4. Financial Overview
12.8.5. SWOT Analysis
12.8.6. Key Developments
12.9. CYTORI THERAPEUTICS INC.
12.9.1. Key Facts
12.9.2. Business Description
12.9.3. Products and Services
12.9.4. Financial Overview
12.9.5. SWOT Analysis
12.9.6. Key Developments
12.10. BAYER
12.10.1. Key Facts
12.10.2. Business Description
12.10.3. Products and Services
12.10.4. Financial Overview
12.10.5. SWOT Analysis
12.10.6. Key Developments
13. APPENDIX
13.1. ABOUT THE INSIGHT PARTNERS
13.2. GLOSSARY OF TERMS
The List of Companies

1. F. Hoffman La Roche
2. Boehringer Ingelheim International GmbH
3. Bristol-Myers Squibb Company
4. arGentis Pharmaceuticals LLC
5. Prometic Life Sciences Inc.
6. Akashi Therapeutics
7. Kadmon Holdings Inc.
8. Emerald Health Pharmaceuticals
9. Cytori Therapeutics Inc.
10. Fibrocell Science Inc.
11. Chemomab
12. Corbus Pharmaceuticals Holdings Inc.
13. Genkyotex
14. Bayer
15. Celgene Corporation.
TIPRE00020949
Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Pricing

Free

20%

customization on Pre-Booking